Purple Biotech (PPBT) Common Equity (2014 - 2026)

Purple Biotech (PPBT) has 11 years of Common Equity data on file, last reported at $9.7 million in Q1 2026.

• Quarterly Common Equity changed N/A year-over-year to $9.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.7 million (changed N/A YoY) and the FY2025 annual result came in at $9.7 million, down 70.48% from the prior year.
• Common Equity was little changed at $9.7 million in Q1 2026 per PPBT's latest filing, from $9.7 million in the prior quarter.
• Across five years, Common Equity topped out at $47.1 million in Q4 2022 and bottomed at $9.7 million in Q4 2025.
• The 5-year median for Common Equity is $32.9 million (2024), against an average of $26.7 million.
• The widest annual swing landed in 2024, when Common Equity retreated 4.04%; it then tumbled 70.48% in 2025.
• Tracing PPBT's Common Equity over 5 years: stood at $47.1 million in 2022, then declined by 27.18% to $34.3 million in 2023, then slipped by 4.04% to $32.9 million in 2024, then tumbled by 70.48% to $9.7 million in 2025, then increased by 0.08% to $9.7 million in 2026.
• Per Business Quant, the three latest PPBT Common Equity figures stand at $9.7 million (Q1 2026), $9.7 million (Q4 2025), and $32.9 million (Q4 2024).

Peer Comparison